GSK’s $10.6 billion agreement to buy Nuvalent is a reminder that the pharmaceutical industry’s deal market is being driven less by cheap targets than by scarce assets that can plausibly change a company’s growth profile before the end of the decade.
The British drugmaker said Tuesday that it will acquire Boston-based Nuvalent for $124 a share in cash, valuing the clinical-stage oncology company at about $10.6 billion. The price represents a 40% premium to Nuvalent’s last closing price, or a 26% premium to its 30-day volume-weighted average price. Net of the cash GSK expects to acquire, the company’s aggregate investment is estimated at $9.4 billion.
For GSK, the transaction is not simply a bolt-on science deal. It is a sizeable bet that precision lung-cancer drugs can help fill a coming revenue gap and make the company’s oncology franchise more credible. The acquired pipeline includes three lung-cancer assets: zidesamtinib, also known as NVL-520, for ROS1-positive non-small cell lung cancer; neladalkib, or NVL-655, for ALK-positive non-small cell lung cancer; and NVL-330, an earlier-stage HER2 inhibitor.
The first two assets are the commercial hinge of the deal. GSK says both have received FDA Breakthrough Therapy and Orphan Drug designations and are under U.S. regulatory review, with target decision dates of Sept. 18, 2026, for zidesamtinib and Nov. 27, 2026, for neladalkib. Subject to approval, both could launch this year. That timing matters because GSK is trying to strengthen its sales base before dolutegravir, its important HIV medicine, faces loss of exclusivity over 2028 to 2030.
The acquisition also shows how much value large drugmakers are willing to assign to assets that are not yet fully commercial but are close enough to market to affect medium-term earnings. GSK said the deal should contribute to revenue growth from 2027, add to core operating profit in 2027 and become accretive to core earnings per share in 2029, after synergies and portfolio reprioritisation. It also said the transaction does not change its 2026 full-year guidance for 7% to 9% growth in core operating profit and core earnings per share.
There is a cost to moving with that urgency. GSK expects low-single-digit percentage dilution to core earnings per share for 2026, 2027 and 2028 if the deal closes in the third quarter. The company plans to fund the acquisition mainly through new and existing debt facilities plus cash, while saying it does not expect an impact on its credit rating and remains committed to a 70 pence expected dividend for 2026. Investors still had reason to test those assumptions, and GSK shares fell more than 2% in Tuesday trading after the announcement.
The market’s caution is understandable. A $10.6 billion all-cash offer for a clinical-stage company leaves less room for regulatory disappointment, launch delays or tougher-than-expected competition. It also comes at a time when many large pharmaceutical companies are being pushed by patent cliffs to buy growth rather than wait for internal research pipelines to mature. In that environment, the best late-stage targets can command prices that make strategic sense only if execution is clean.
Nuvalent brings some features that help explain the premium. Its programs target genetically defined cancers where drug design, tolerability and central nervous system activity can matter greatly because lung cancer often spreads to the brain and existing treatments can run into resistance or side-effect limits. Royalty Pharma’s December agreement to acquire low-single-digit royalty interests in neladalkib and zidesamtinib also pointed to outside financial interest in the same assets before GSK moved for the whole company.
The deal is structured as a tender offer for Nuvalent’s Class A and Class B shares, expected to begin within 10 business days, followed by a second-step merger at the same price for any remaining shares. Completion is subject to customary conditions, including a majority of Nuvalent shares being tendered and U.S. antitrust waiting-period requirements.
For GSK, the strategic message is clear. The company is choosing to spend heavily now for assets that could reach patients soon, instead of waiting for a cheaper but less certain entry point. That makes the Nuvalent acquisition a test of whether disciplined oncology M&A can still create value when everyone in the sector knows that late-stage growth is scarce.